Clinical

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

Andrew Kuykendall, MD, lead investigator for the VERIFY trial supporting the approval, said rusfertide is used to treat erythrocytosis in polycythemia vera.

Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, said.

Keith Bellovich, DO, of Strive Health, discusses how the new CKM guideline unifies cardiology, nephrology, and endocrinology care.

August authors Jeff Romine, PhD, and Kofi Essel, MD, MPH, found grocery assistance linked to fewer diabetes complications and better medication adherence.

Led by the moderator, the expert mental health experts examined how tolerability shapes agent selection, with Wilkinson highlighting metabolic side effects and akathisia — most pronounced with aripiprazole — as key counseling points, alongside the value of anticipatory guidance in building patient trust and preventing premature discontinuation.

Dr. Chung welcomes Dr. Robert Gish to the program, who introduces himself as medical director of the Hepatitis B Foundation, an academic appointee at UCSD, Loma Linda, and the University of Nevada, Las Vegas, and a clinician who sees patients with hepatitis B across five active clinic sites, where the disease makes up roughly 10% of his practice.

Led by the moderator, the panelists discussed persistent efficacy, tolerability, and adherence gaps in antidepressant treatment, noting that only about 60% of patients with MDD receive treatment and roughly 30% develop treatment resistance, with early adverse effects often undermining adherence before benefits take hold.

Combination regimens, monoclonal antibodies, and gene therapy aimed at de-integrating viral DNA are reshaping what a hepatitis B cure could look like. This episode looks ahead to the next five to ten years

Tara Graff shared her enthusiasm for the remarkable expansion of second-line treatment options that has occurred within a single year providing community oncologists with multiple highly effective, non-chemotherapy regimens that can be meaningfully tailored to individual patient characteristics and preferences, moving definitively away from a one-size-fits-all approach and toward truly personalized RRFL care.

Long-acting injectables help patients overcome stigma and adherence barriers in HIV care, explained Matthew H. Herrmann, MD, AAHIVS.

A researcher explains why cardiac diagnoses, not all-cause mortality, are the most reliable finding in her vaccine-safety study.

Age shapes more than pill-swallowing ability in pediatric vitiligo care. Dr. Lal explains how activity level, motivation, and comorbidities guide the choice between topical and oral therapy in younger patients, more than any single BSA threshold.

Trial enrollment ranges become policy boundaries in practice. Dr. Desai explains how broader BSA inclusion supports patients with widespread disease, while Jason describes how narrower criteria let payers manage the bulk of cases through topical therapy first.

Five-year EXPLORER-LTE data show sustained LVOT gradient reductions and NYHA class improvements in patients with obstructive HCM.

Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.

A cardiovascular researcher explains why her team compared cardiac risks of COVID-19 infection and vaccination head-to-head.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

A Chest study of 1576 patients finds a 20% emphysema threshold best predicts survival and lung function decline in fibrotic ILD.

New multi-center registry data confirm MAC as the dominant cause of NTM pulmonary disease, while culture conversion with standard therapy still fails in nearly half of patients.

Better risk stratification, more tolerable regimens, and outcome measures beyond culture conversion top the list of unmet needs Dr. Losier identifies for MAC and NTM pulmonary disease heading into ATS 2026.

Systematic review maps 410 lymphoma antibody drug conjugates clinical trials, revealing limited diversity beyond MMAE, few survival end points, and scarce biomarkers in DLBCL and classical Hodgkin lymphoma.

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said.